Joel Greenblatt fit · Magic Formula — high ROIC + cheap EV/EBIT
Is Acadia Pharmaceuticals Inc. (ACAD) a Joel Greenblatt Stock?
Partial match — either cheap or high-quality, but not both.
62/100
CMixed signals
2/5 criteria passed
Joel Greenblatt's Criteria, Applied to ACAD
EBIT/EV yield ≥ 10%
key3.6%
ROIC ≥ 25%
key25.2%
EV/EBIT ≤ 12
27.7x
Gross margin ≥ 30%
91.9%
How ACAD Scores on Other Strategies
Live Financial Snapshot
Market cap
$4.65B
P/E (TTM)
19.0x
ROIC (TTM)
25.22%
Gross margin
91.92%
Frequently Asked Questions
What is ACAD's Joel Greenblatt fit score?
ACAD scores 62/100 on our Joel Greenblatt fit engine — grade C. Partial match — either cheap or high-quality, but not both.
Does Joel Greenblatt actually own ACAD?
Our score is computed from financial fundamentals against Joel Greenblatt's published criteria. We don't claim that Joel Greenblatt personally owns or recommends ACAD.
How often is this score updated?
ACAD's Joel Greenblatt fit score is recomputed daily from the latest TTM financials.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Joel Greenblatt personally owns or recommends ACAD.